

- Strongyloides stercoralis*/strongyloidiasis
 adult T-cell leukemia/lymphoma and, 225e-4
 clinical features of, 152e-5t, 1414t, 1415
 diagnosis of, 152e-5t, 245e-1, 245e-3t, 245e-5t, 245e-6t, 1416
 eosinophilia in, 245e-6t, 765t, 1687
 epidemiology of, 152e-8, 245e-3t, 765t, 1415
 incubation period for, 152e-5t
 life cycle of parasite, 245e-3t, 1414t, 1415, 1415f
 in returning war veterans, 152e-5t, 152e-8
 in travelers, 797
 treatment of, 152e-5t, 246e-9, 1414t, 1416
⁹⁰Strontium exposure, 263e-3t, 263e-6t
 Strontium ranelate, 2503
⁸⁹Strontium therapy
 for bone pain, 61, 474
 for metastatic bone disease, 119e-4
 for metastatic breast cancer, 530
 Structure (quality theory), 12e-2
 Struma ovarii. *See* Teratoma, ovarian
 Struvite stones, 1871. *See also* Nephrolithiasis
 ST segment elevation, 1456, 1457, 1457f, 1457t
 ST-segment elevation myocardial infarction (STEMI), 1599. *See also* Myocardial infarction
 circadian variations in, 1599
 classification of, 1602t
 clinical features of, 96, 96t, 1599–1600
 complications of, 1602, 1607
 arrhythmias, 1608–1609, 1609f
 cardiogenic shock, 1608
 heart failure, 1607–1608
 hypovolemia, 1607–1608
 left ventricular aneurysm, 1610
 pericarditis, 1610
 recurrent chest pain, 1609–1610
 right ventricular infarction, 1608
 thromboembolism, 1610
 ventricular dysfunction, 1607
 definition of, 1602t
 diagnosis of
 biomarkers, 1600–1601, 1601f
 CMR, 1601–1602
 ECG, 269e-3f, 269e-4f, 297e-2f, 1456–1457, 1457f, 1457t, 1599f, 1600
 echocardiography, 271e-1f, 271e-1v, 1601
 physical examination, 1500
 radionuclide imaging, 1601
 differential diagnosis of, 1600
 epidemiology of, 1599
 hemodynamic assessment in, 1607
 incidence of, 1593, 1594f, 1599
 nonspecific reaction to, 1601
 painless, 1600
 pathophysiology of, 1599. *See also* Atherosclerosis; Coronary artery disease (CAD)
 pulmonary edema in, 1764
 recurrent, 1610
 risk factors for, 1599
 risk stratification and management after, 1610
 secondary prevention after, 1610–1611
 stages of, 1600
 TIMI grading system, 1605
 treatment of
 ACE inhibitors, 1607
 activity restriction, 1606
 antiplatelet agents, 1603, 1606
 antithrombotic therapy, 1606
 ARBs, 1607
 beta blockers, 1603–1604, 1607
 bowel management, 1606
 diet therapy, 1606
 in emergency department, 1603, 1604f
 fibrinolytic therapy, 1605
 hospital/coronary care unit, 1605–1606
 implantable cardioverter-defibrillator, 1609, 1609f
 integrated approach to, 1604f, 1605
 limitation of infarct size, 1604
 morphine, 1603
 nitrates, 1603, 1607
 oxygen therapy, 1603
 pacemaker, 1609
 pain control, 1603–1604
 PCI
 indications for, 1604–1605, 1604f
 left main, 297e-3–4, 297e-3–4v, 297e-4f
 with manual thrombectomy, 297e-2, 297e-2f, 297e-2v
 rescue, 1605
 time from symptom onset to, 1603, 1603f
 urgent, 1605
 prehospital care, 1602, 1603f
 reperfusion therapy, 1604, 1604f, 1605
 sedation, 1606
 Stupor, 1771
 Sturge-Weber syndrome, 441e-38f
 STW 5, 263
 Sty (hordeolum), 199
 Stylostome, 2745
 Subacromial bursitis, 2247
 Subacute combined degeneration, 2659
 Subacute necrotizing myelopathy, paraneoplastic, 614t
 Subacute sclerosing panencephalitis (SSPE), 900, 1298
 Subaortic stenosis, 1525
 Subarachnoid hemorrhage, 1784
 vs. bacterial meningitis, 888
 clinical features of, 1785
 in critically ill patient, 1735, 1784
 diagnosis of, 1786, 1786f
 DVT prophylaxis after, 1787
 ECG in, 1457, 1458f
 epidemiology of, 1784
 etiology of, 1784–1785
 fundus examination in, 1773
 grading of, 1785t
 headache in, 107t, 108, 1785
 at high altitudes, 476e-4
 hyponatremia in, 299, 1785–1786
 hypothermia in, 478e-1
 neurologic deficits after, 1785–1786
 pathophysiology of, 1785
 in polycystic kidney disease, 1852
 treatment of, 1786–1787
 Subclavian artery, occlusion of, 2576
 Subconjunctival hemorrhage, 199
 Subcortical aphasia, 179
 Subcutaneous panniculitis-like T-cell lymphoma, 135e-4, 708
 Subdural empyema, 783, 903
 approach to the patient, 883–884, 884–885f
 clinical features of, 903–904
 definition of, 903, 903f
 diagnosis of, 904, 904f
 differential diagnosis of, 904
 epidemiology of, 903
 etiology of, 903, 1097
 pathophysiology of, 903
 prognosis of, 904
 treatment of, 904
 Subdural hematoma
 acute, 457e-3, 457e-3f
 chronic, 457e-3–4, 457e-3f
 coma in, 1772
 dementia in, 2608
 imaging in, 441e-34f, 1772f
 weakness in, 156
 Suberosis, 1681t
 Subeschar clays, 166e-3
 Subfascial endoscopic perforator surgery, 1653
 Sublingual space infections, 235
 Subluxation, 2219, 2219t
 Submandibular space infections, 233, 235, 236, 1097
 Submucosal plexus, 264
 Subperiosteal abscess, 231
 Sub-Saharan Africa
 health care delivery in, 13e-6–7
 health workforce and disease burden in, 13e-3, 13e-4f
 life expectancy in, 13e-3f
 Substance P
 in neural control of gastrointestinal system, 264
 pain and, 88, 88f
 in swallowing, 255
 Substance use disorders. *See also* Injection drug users; *specific substances*
 delirium in, 168–169
 dementia in, 2608
 genetic considerations in, 465e-1
 neuropathology of, 444e-4, 465e-4, 465e-5t
 pathogenesis of, 465e-3, 465e-3f
 polydrug, 469e-5
 prevalence of, 2708
 in women, 6e-5
 Substernal goiter, 2301
 Substrate reduction therapy, 432e-5
 Succession, 86e-1t
 Succimer (DMSA), 472e-2–3t
 Succinate dehydrogenase (SDH) enzyme, 2329, 2332
 Succinylcholine, 34t, 310
 Suck response, 2539
 Sucralfate, 263, 1920t, 1921, 1930
 Sudan virus disease, 1323, 1325f, 1326f
 Sudden cardiac death, 1764
 circadian variations in, 194
 definition of, 1764, 1765t
 epidemiology of, 1764–1765, 1766f
 etiology of, 1764–1765, 1765t
 genetic considerations in, 1765
 in heart failure, 1514
 in hypertrophic cardiomyopathy, 1569–1570, 1570t
 incidence of, 1764
 pathology of, 1766
 prediction of, 1766–1767, 1767f
 prevention of, 1766–1767, 1767f, 1770–1771
 in young adults and adolescents, 1764, 1767
 Sudeck's point, 1979, 1979f
 Sudomotor function, 2640–2641, 2641t
 Sufentanil, 1741
 Sugars, malabsorption of, 269
 Suicide
 deaths from, 6e-1t, 56t
 physician-assisted, 67–68, 67t
 worldwide, 17
 Sulbactam, 933, 938, 1037, 1037t. *See also* Ampicillin-sulbactam
 Sulfacetamide, 199
 Sulfadiazine
 action of, 931t, 932
 adverse effects of, 246e-4t
 drug interactions of, 246e-4t
 in pregnancy and lactation, 246e-4t
 resistance to, 931t
 for toxoplasmosis, 903, 1404
 for toxoplasmosis prophylaxis, 1251–1252t
 for Whipple's disease, 1094
 Sulfadoxine, 246e-4t, 1378t, 1384
 Sulfamethoxazole
 action of, 931t, 932
 adverse effects of, 246e-4t, 377, 382, 656t
 drug interactions of, 246e-4t
 for *Nocardia* infections, 1087
 in pregnancy and lactation, 246e-4t
 resistance to, 931t
 Sulfasalazine
 adverse effects of, 138, 646t, 1857, 1959, 2146t
 for ankylosing spondylitis, 2173
 for IBD, 1959, 1959t
 monitoring during treatment with, 2146t
 for psoriatic arthritis, 2177
 for reactive arthritis, 2175
 for rheumatoid arthritis, 2145, 2146t
 Sulfhemoglobin, 249
 Sulfisoxazole, 931t, 932
 Sulfocysteinuria, 434e-2t
 S-Sulfo-L-cysteine metabolism disorders, 434e-2t
 Sulfonamides
 action of, 931t, 932, 932f
 adverse effects of
 cross-sensitivity and, 385
 cutaneous, 25e-6f, 353, 360, 361, 366